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Abstract
Background: Myeloperoxidase (MPO), an important element of the microbicidal activity of neutrophils, generates 
hypochlorous acid (HOCl) from H2O2 and chloride, which is released into body fluids. Besides its direct microbicidal 
activity, HOCl can react with amino acid residues and HOCl-modified proteins can be detected in vivo.
Findings: This report is based on binding studies of HOCl-modified serum albumins to HIV-1 gp120 and three different 
neutralization assays using infectious virus. The binding studies were carried out by surface plasmon resonance 
spectroscopy and by standard ELISA techniques. Virus neutralization assays were carried out using HIV-1 NL4-3 virus 
and recombinant strains with CXCR4 and CCR5 coreceptor usage. Viral infection was monitored by a standard p24 or X-
gal staining assay. Our data demonstrate that HOCl-modified mouse-, bovine- and human serum albumins all bind to 
the HIV-1 NL4-3 gp120 (LAV) glycoprotein in contrast to non-modified albumin. Binding of HOCl-modified albumin to 
gp120 correlated to the blockade of CD4 as well as that of V3 loop specific monoclonal antibody binding. In 
neutralization experiments, HOCl-modified serum albumins inhibited replication and syncytium formation of the X4- 
and R5-tropic NL4-3 isolates in a dose dependent manner.
Conclusions: Our data indicate that HOCl-modified serum albumin veils the binding site for CD4 and the V3 loop on 
gp120. Such masking of the viral gp120/gp41 envelope complex might be a simple but promising strategy to 
inactivate HIV-1 and therefore prevent infection when HOCl-modified serum albumin is applied, for example, as a 
topical microbicide.
Background
An important event in HIV-1 infection is the step-by-step
binding of the external envelope complex, the gp120/
gp41 trimer, to (i) CD4 [1] and to (ii) a family of seven-
transmembrane chemokine receptors including CXCR4
and CCR5 which are the two major coreceptors [2] on the
cellular membrane as well as to (iii) heparan sulfate struc-
tures [3]. HIV-1 entry can therefore be inhibited by hepa-
ran sulfate [4], its analogs [5] or other synthetic
polyanions [6], ligands for CD4 [7], CXCR4 [8] or CCR5
[9], and by factors that bind to gp120 like neutralizing
antibodies [10]. Since HIV-1 variability is prodigious,
viral escape to all these antiviral substances has been doc-
umented and therefore there is a pressing need to find
new strategies to efficiently block HIV-1 infection.
In 1992, Klebanoff and coworkers [11] showed that
stimulated polymorphonuclear (PMN) cells released an
unknown factor which neutralized HIV-1. PMN from
patients with hereditary myeloperoxidase (MPO) defi-
ciency indicated that the antiviral activity was correlated
with the presence and the release of the enzyme into cell
culture medium. Adding MPO to PMN-(MPO-deficient)
cell cultures restored the ability to block HIV-1 infection
[11,12]. In addition to MPO, the presence of two other
factors, H2O2 and chloride, was absolutely necessary to
observe the antiviral activity in cell culture supernatants
of stimulated PMN cells. Since the enzyme MPO cata-
lyzes the reaction between H2O2 and chloride to generate
HOCl (bleach), Klebanoff and coworkers [12] suggested
that this product of the MPO/H2O2/halide system was
directly responsible for HIV inactivation. A clue as to the
substrate of the MPO/H2O2/halide system was provided
by the detection of HOCl-modified proteins in human
tissue by a specific monoclonal antibody (clone 2D10G9)
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[13]. This antibody recognized an HOCl-modified pro-
tein in glomerular and tubulointerstitial inflammatory
and fibrotic lesions and its binding was inhibited by
HOCl-modified human serum albumin (mHSA) [14,15].
Recently we demonstrated that mHSA was active
against West Nile virus (WNV) [16]. Low doses of HOCl-
modified human serum albumin (mHSA) inactivated
WNV entry into VeroB4 cells in vitro and we observed an
interaction between mHSA and the domain III of the
WNV external envelope. Similar to WNV, HIV-1 also
enters its target cell following membrane fusion of the
viral envelope and the plasma membrane and it is con-
ceivable that enveloped viruses share common functions
to promote membrane-membrane contact to allow bind-
ing of cell membrane-anchored receptors.
Here we report, that mHSA, mBSA (bovine) and
mMSA (mouse) bind to recombinant HIV-1 gp120 of the
laboratory strain NL4-3. Binding of HOCl-modified
serum albumins to gp120 also inhibited binding of
recombinant CD4 (rCD4) and V3 loop-specific antibod-
ies. All three HOCl-modified serum albumins inhibited
viral infection and syncytium formation in a dose depen-
dent manner.
Method
Viruses, Cell Lines, Env expression plasmids, and HIV 
Reagents
HIV-1 strain NL4-3, an X4-monotropic laboratory iso-
late, was used for virus inhibition tests. HeLa-P4 cells
expressing human CD4, CXCR4 were kindly provided by
Matthias T. Dittmar, University Heidelberg. GHOST-
CXCR4 cells, antibody sera, monoclonal antibody, and
gp41 (ARP671, spanning the entire extracellular domain
of HIV-1 gp41MN) were obtained from the European Vac-
cine Against AIDS Programme (EV A, Potters Bar , UK).
Recombinant HIV-1 gp120 (LAV, CXCR4 monotropic,
identical to NL4-3 gp120, glycosylated) and human rCD4
(soluble form, transmembrane region removed, glycosy-
lated) was obtained from Protein Sciences Corporation,
Meriden, CT, USA. These commercially proteins were
expressed in insect cells by a baculovirus vector system,
secreted in the serum-free cell culture medium and puri-
fied under non-denaturing conditions. The env expres-
sion plasmid pSVATGrev carries a subgenomic HIV NL4-
3 fragment coding for rev, vpu and env under the tran-
scriptional control of the SV40 early promotor. The plas-
m i d  s e q u e n c e  c a n  b e  o b t a i n e d  u p o n  r e q u e s t .
Construction of NL4-3 mutants with R5X4 and R5 tro-
pism and mutants lacking N-glycosylation site g15 was
carried out as described earlier [17].
Modification of serum albumins by HOCl
The HOCl reaction was carried out as described in the
literature [18] with modifications. In brief, freshly pre-
pared HOCl was added to an aqueous solution of serum
albumin (1 gr/liter phosphate buffered saline, pH 7.5).
The concentration of HOCl was monitored by UV spec-
troscopy (ε = 375 mol/cm liter). Serum albumin was
treated with HOCl at different molar ratios (serum albu-
min:HOCl, 1:10, 1:20, 1:100, 1:200, 1:500, 1:1000,
1:10000). After incubation for 30 min at RT, remaining
HOCl was inactivated by adding the antioxidant 2 amino-
ethanesulfonic acid (taurine, final concentration 5 gr/l).
The mixture was incubated again for 30 min at RT. Purifi-
cation of the HOCl-modified serum albumin and the
elimination of remaining 2 aminoethanesulfonic acid was
achieved by concentrating the reaction mixture to a final
volume of 50 ml by ultrafiltration (GE Healthcare, hollow
fibre column UFP-10-C 3X2MA, membrane nominal-
molecular-weight cutoff 10 kD) and then further purified
by a continuous ultrafiltration process using the Quix-
Stand® apparatus (GE Healthcare). A total volume of 20
litres of water was slowly added over a time period of 48 h
to purify the mHSA product which was continuously
pumped over the hollow fibre column at a maximum
pressure of 15 PSI. After this ultrafiltration process the
solution (400 ml) was again concentrated to a final vol-
ume of 50 ml. The final yield of HOCl-modified serum
albumin was between 250-500 mg/50 ml (i.e. 25-50%).
ELISA binding studies
ELISA plates (Nunc, MaxiSorb) were coated with gp120
(3 μg/ml in carbonate buffer 0.1 M NaHCO3, 0.1 M
Na2CO3, pH 9.6). To each well of a 96-well plate 100 μl of
the gp120 solution was added and the plates were sealed
with adhesive foil (Sarstedt) and incubated at 8°C over-
night. Subsequently 250 μl of a BSA solution (20 μg/ml
PBS) was added to each well and the plates incubated for
1 h at room temperature. After blocking, the plates were
washed 5-times with PBS containing 0.05% Tween 20
(PBST). Modified serum albumin was added to the wells
in a total volume of 50 μl PBS. After incubation for 30
min. rCD4 or antibody was added to each well in a total
volume of 50 μl PBS. The plates were incubated for 1 h at
room temperature and then washed 5-times with PBST.
To detect gp120-bound rCD4 we used the anti-CD4
mouse monoclonal antibody NCL-CD4-1F6 (Novocas-
tra). Bound anti-CD4 antibody was detected by a second-
ary anti-mouse HRP-antibody conjugate diluted 1:500 in
PBS (BioRad). Bound gp120-specific monoclonal anti-
body was monitored directly using the anti-mouse-HRP-
antibody conjugate (BioRad). After binding of the sec-
ondary antibody, the plates were washed 5 times with
PBST and 5 times with PBS. To each well 100 μl of a com-
mercially available one-component ready to use solution
of 3,3',5,5'-tetramethylbenzidine (TMB, Sigma Aldrich)
was added, the reaction stopped with 1 M H2SO4, and the
plate read at 450 nm.Polzer et al. BMC Research Notes 2010, 3:155
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Biosensor binding studies
Purified recombinant LAV gp120 (1 μg/100 μl 10 mM
NaOAc pH 4.0) was immobilized by NHS/EDC coupling
on a dextran coated, CH-activated C5 sensorchip (Bia-
core, Sweden) at densities yielding 3500-5000 response
units (RU). Surface plasmon resonance was carried out
using a Biacore 1000. Binding to immobilized proteins
diluted in HBS-EP buffer (Biacore, Sweden) was tested at
various concentrations at a flow rate of 5 μl/min for a
period of 6 min.
Cell proliferation assays
To each well of a 96-well plate, containing 10.000 CD4+
HeLa-P4 cells inhibitor and control proteins were added
at various concentrations and the cells were incubated for
48 h. Thereafter the medium was changed and 10 μl
MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazo-
lium bromide) solution (5 mg/ml MTT dissolved in PBS
pH 7.4) was added. The plates were incubated at 37°C for
4 h after which the medium was removed and 100 μl of
lysis buffer (9.94 ml DMSO, 60 μl HCl, 1 g SDS) added to
each well. The plates were incubated for 10 min at 37°C.
Absorbance was measured at 560 nm with background
subtraction at 630 nm. Cells were cultured in Dulbecco's
Modified Eagle Medium (DMEM, Gibco) including 10%
fetal calf serum (FCS, Biochrom KG, Berlin, Germany).
DMEM is composed of D-glucose, phenol red, inor-
ganic salts, vitamins and a mixture of 15 free amino acids
containing the HOCl-sensitive amino acids Arg (0.4 M),
Cys (0.2 M), His (0.2 M), Lys (0.8 M), Met (0.2 M), Phe
(0.4 M) and Tyr (0.4 M).
Virus inhibition
(a) GHOST-CXCR4 cells were infected with 1000 TCID
(Tissue Culture Infective Dose) of the X4-tropic labora-
tory strain NL4-3. To study inhibition, virus was given to
the cells after preincubation of cells with modified serum
albumin for 30 min. Cell culture supernatants were tested
on day 5 for p24-antigen by a standard p24-antigen
ELISA. GHOST cells were cultured in DMEM (Gibco)
including 10% FCS (Biochrom KG). (b) TZM-bl cells
were infected with virus supernatant representing an
infectious dose of 500 foci/96-well. Viral entry into TZM
bl cells causes the expression of β-galactosidase, which
can be monitored 2 days after infection. To detect β-
galactosidase-expressing cells, the cell culture superna-
tant was removed and the cell layer was treated with
0.25% glutaraldehyde in phosphate-buffered saline (PBS,
5 min, RT) and washed three times with PBS. To stain
infected cells, 100 μl of the X-gal solution (0.5 mg X-gal
[5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside]/
ml, 1 mM MgCl2, 3 mM potassium ferrocyanide, 3 mM
potassium ferricyanide in PBS) was added to each well
and the plates were incubated at 37°C. The staining reac-
tion was monitored by microscopy. Finally, the cell layer
was washed again with PBS and blue foci were counted.
Inhibition of syncytium formation
GHOST CXCR4 cells (104 cells per 96-well) cultured in
DMEM/10% FCS were infected with 1000 TCID of the
HIV laboratory isolates NL4-3 and were also infected in
the presence of 50 μg mHSA per ml cell culture medium
(DMEM/10% FCS). Virus and mHSA were added to the
cells simultaneously. The cultures were assessed micro-
scopically 5 days after infection by visualization of
induced syncytia and cell layer destruction. To visualize
syncytia, cell layers were treated with 3% formalin for 10
min to inactivate virus and then fixed with methanol
(Solution 1 of the Azur B and Eosin G based Hemacolor®
rapid staining set, Merck, Germany) for 5 min. After fixa-
tion, cells were stained with color reagent red (solution 2
of the Hemacolor® staining set) for 30 sec followed by a
staining with color reagent blue (solution 3 of the Hema-
color®  staining set) for 30 sec. Alternatively, HeLa-P4
cells, cultured in DMEM/10% FCS, expressing human
CD4, CXCR4 were transfected with 1 μg pSVATGrev
plasmid. This plasmid expresses the gp160 protein pre-
cursor, which is processed and expressed on the outside
of the cellular membrane as the functional gp120/gp41
complex. Cells were transfected for induction of syncytia
and mHSA was given to the cells 30 min after transfec-
tion. Syncytium formation was assessed after 28 h by
standard phase contrast microscopy.
Results
Generation of HOCl-modified serum albumins
In a first experiment we tested different samples of the
HOCl-modified HSA, which were generated by using dif-
ferent HOCl concentrations, in a syncytium inhibition
assay. In HIV-1 cell cultures, infected cells fuse with
other, non-infected CD4+ target cells. Cell-cell fusion is
known as syncytium formation. Syncytium formation is
the result of the binding of gp120, which is present on
membranes of the infected cells, to the receptors on the
target cells and subsequent insertion of the gp41 N-ter-
minus into the host membrane. This gp120-receptor
binding event promotes recurring cell-cell fusion which
leads to the generation of large syncytia. The mHSA sam-
ples generated with low HOCl concentrations (molar
ratios HSA:HOCl 1:10 and 1:50) showed no inhibitory
effect on syncytium formation (Figure 1). At higher con-
centrations (molar ratio 1:100) an inhibitory effect of
mHSA was detected with 90% inhibition at a concentra-
tion of approximately 50 μg/ml. The mHSA samples pro-
duced at molar ratios 1:1000 and 1:10.000 showed strong
inhibition with 90% at 10 μg/ml and complete inhibition
of gp120-induced syncytium induction at 20 μg/ml. Thus,
HSA treated with higher concentrations of HOCl isPolzer et al. BMC Research Notes 2010, 3:155
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transformed in to an an tiviral form in c on trast t o HSA
samples treated with low HOCl doses.
Binding of gp120 to HOCl-modified serum albumins
Since a 1000-fold molar HOCl excess was sufficient to
transform HSA into a viral entry inhibitor we generated
HOCl-modified samples of three serum albumins from
human, mouse and bovine by using a 1000-fold excess of
HOCl. Using these three serum albumin preparations, we
studied binding of mHSA, mBSA and mMSA to LAV
(NL4-3) gp120 by surface plasmon resonance spectros-
copy (SPR) (Figure 2a, c, e). The experiment demon-
strated that serum albumin modified by a 1000-fold
molar excess of HOCl bind to the immobilized gp120. No
binding of mHSA, mBSA and mMSA to gp41 immobi-
lized on a biosensor (binding < 5 RU, data not shown) was
observed. Thus, binding was specific for gp120 envelope.
Bound protein was removed from the gp120-biosensor by
treatment with 100 mM HCl and 100 mM NaOH. This
regeneration procedure retained the ability of immobi-
lized gp120 to bind rCD4 and V2- and V3-loop specific
antibodies. Also no binding to gp120 was measured using
normal, non-modified HSA, BSA and MSA (Figure 2b, d,
f). In these control experiments response units (RU) in
SPR were also below 5 RU. Binding of HOCl-modified
proteins was compared to gp120-binding of rCD4 and
gp120-specific antibodies (Figure 2g). At 50 μg/ml the
modified proteins showed between 50-70% of the gp120
binding activity observed with rCD4 at 10 μg/ml. Binding
of antibodies generated by immunization with CHO-
derived SF2-gp120 (Serum ADP429) or by a V3 loop pep-
tide (IRIQRGPGRAFTIGC) (mab EVA 3047) showed
binding responses at 1:80 dilution (Serum ADP429) or 25
μg/ml (mab EVA 3047) about 30 40 times as high as the
HOCl-modifed serum albumins at 50 μg/ml.
Blocking of rCD4 and antibody binding to gp120
Next we investigated whether binding of rCD4 or V2-
and V3-loop specific antibodies to gp120 was influenced
by HOCl-modified serum albumin (Figure 3). These
binding studies showed that mHSA, mBSA and mMSA
completely inhibited binding of rCD4 to LAV gp120 at
concentrations above 10 μg/ml (Figure 3a). In control
experiments, neither binding of the anti-CD4-1F6 mono-
clonal antibody to CD4 nor binding of the secondary
HRP-conjugated antibody was inhibited by HOCl-modi-
fied serum albumins (data not shown). In addition to
rCD4, binding of V3 loop-specific monoclonal antibodies
was reduced but not completely inhibited at 10 μg/ml
(Figure 3b). In contrast to binding of V3 loop antibody,
binding of V2 loop antibody was not inhibited by mHSA,
mBSA or mMSA.
Virus neutralization by HOCl-modified serum albumins
For evaluation of virus neutralizing activity, the three
HOCl-modified serum albumins were first tested in an
MTT-assay (Figure 4a). Using up to 200 μg/ml of HOCl-
modified protein, which is at least 10-times of the mHSA
concentration necessary to neutralize NL4-3 >95%, we
observed no anti-cellular activity in comparison to nor-
mal serum albumin. As shown in Figure 4b, virus infec-
tion was inhibited by mHSA, and mBSA in a dose-
dependent manner to >95% and >90% at a concentration
of each 20 μg/ml. Virus inhibition by mMSA was slightly
lower and inhibition >90% was observed using 50 μg/ml
of mMSA. In addition to viral infection we also tested the
inhibition of syncytium formation. As shown in Figure 5,
syncytium formation induced by virus strain NL4-3 (Fig-
ure 5b) was completely inhibited by mHSA at a concen-
tration 50 μg/ml (Figure 5c). As demonstrated before
(Figure 4a) mHSA did not inhibit cell proliferation and, in
agreement with this observation, cell morphology and
staining of the nucleus proved vitality of the GHOST cells
grown in the presence of 50 μg mHSA/ml (Figure 5a, c).
Since syncytium formation is based on the presence of
viral envelope and viral receptors on the cellular surface,
syncytia can be simply induced by gp160 expression.
Therefore, HeLa P4 cells were transfected with gp160
expression vector pSVATGrev. Transfected HeLa P4 cells
expose the gp120/gp41 complex on their outer mem-
brane surface and syncytia could be detected after 28 h
(Figure 5e). In contrast to non-transfected cells, incuba-
tion with mHSA did not show any syncytia (Figure 5d).
Figure 1 Effect of HOCl on HSA and the ability to inhibit syncy-
tium formation. To test the transformation effect of HOCl on HSA, 
mHSA samples were produced, which were generated using different 
HOCl:HSA ratios. The different mHSA preparations were tested for the 
inhibition of gp120/gp41-induced syncytia. HeLa-P4 cells were trans-
fected with pSVATGrev plasmid expressing the NL4-3 (LAV) env. Syncy-
tia were visualized by a standard staining procedure (Hemacolor®, 
Merck) and the nuclei of fused cells were counted. Shown are the av-
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Figure 2 Binding of HOCl-modified serum albumins to gp120. (a-f) Binding of HSA, BSA, MSA and HOCl-modified albumins mHSA, mBSA, mMSA 
(protein:HOCl molar ratio 1:1000) to LAV-gp120 was tested by surface plasmon resonance spectroscopy (Biacore 1000, GE Healthcare). Purified LAV 
gp120 (10 μg/ml, Protein Sciences Corporation) was covalently linked using EDC/NHC to a dextran coated, CH-activated sensor chip (CM5, GE Health-
care). After blocking with ethanolamine the biosensor was washed three times with 30 μl 100 mM NaOH and 30 μl 100 mM HCl (flow rate 5 μl/min). 
Proteins were tested for binding at 1, 5, 10, 25 and 50 μg/ml at a flow rate of 5 μl/min. (g). Binding of mHSA, mBSA and mMSA (values marked by the 
black arrow in Figure 1a, 1c and 1e) was compared to the binding of CD4, and gp120-specific antibodies to a LAV gp120 coated CM5 biosensor. 
ADP429: anti-serum, derived from HIV-1 SF2 gp120-immunized sheep (AIDS reagent project, NIBSC, UK). EVA3047: monoclonal antibody, derived from 
IRIQRGPGRAFTIGC-peptide immunized mice (AIDS reagent project, NIBSC, UK).Polzer et al. BMC Research Notes 2010, 3:155
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As demonstrated in Figure 5f, incubation of pSVATGrev
transfected cells with mHSA (50 μg/ml) again totally
inhibited syncytium formation.
Next we investigated the effect of mHSA against infec-
tion of V3 loop recombinant NL4-3 viruses of X4, R5X4
and R5 tropism. The tropism was switched due to the
exchange of the V3 loop as described earlier [17]. In addi-
tion we also tested mHSA against NL4-3 mutants which
lack the N glycosylation site g15 within the V3 loop. As
Figure 3 Inhibition of CD4 and antibody binding to gp120. Bind-
ing of CD4 or antibody, in the presence of mHSA, mBSA and mMSA, to 
LAV gp120 was tested by ELISA. ELISA plates were coated with LAV 
gp120 (1 μg/ml, Protein Sciences Corporation) over night. After gp120 
binding, the wells were coated using BSA (20 mg/ml). Modified serum 
albumin was added to the wells and (a) CD4 (1 μg/ml, Protein Sciences 
Corporation) or (b) antibody diluted in phosphate buffered saline (PBS) 
pH 7.5, was added 30 min later. After 1 hour, the plates were washed 
5-times with PBS. Binding of CD4 to gp120 was carried out at various 
mSA concentrations. Gp120-bound CD4 was detected by a CD4 spe-
cific mouse monoclonal antibody (NCL-CD4-1F6, Novocastra) fol-
lowed by a staining with an anti-mouse HRP-antibody conjugate 
(BioRad). Shown are the averages of triplicate wells. Binding of V2- and 
V3-loop-specific monoclonal antibodies (mab) was carried out in the 
presence of 10 μg/ml of mHSA. Gp120-bound antibody was detected 
using an anti-mouse-HRP-antibody conjugate (BioRad). Antibodies 
were designated according to the repository reference of the Central-
ized Facility for AIDS Reagents. In brackets: originators antibody desig-
nation. All measurements were carried out in triplicates. White 
symbols: V2 loop specific mab. Black symbols: V3 loop-specific mab.
















































































































































































































































Figure 4 Inhibition of NL4-3 infection. (a) Effects of HOCl-modified 
serum albumins (molar ratio 1:1000) on cell growth. HeLa-P4 cells were 
cultured in the presence of MTT and various concentrations of mHSA, 
mBSA and mMSA (white symbols, 1, 5, 20 and 50 μg per ml; Black sym-
bols, non-modified serum albumins). Cells were seeded at 104 cells per 
well in 96-well plates in triplicate. After adding the yellow tetrazolium 
salt MTT, metabolically active cells produced purple formazan. The 
amount of formazan was measured at 530 nm and is a correlate for cell 
viability and proliferation. (b) NL4-3 neutralization by HOCl-modified 
serum albumins (molar ratio 1:1000). HeLa-P4 cells were infected with 
1000 TCID of the HIV-1 laboratory strain NL4-3. Shown are the averages 
of triplicate wells. Infection was monitored 5 days after infection by a 
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Figure 5 Inhibition of NL4-3 and gp120-induced syncytium formation. (a-c) Inhibition of virus induced syncytium formation. GHOST-CXCR4 cells 
were infected with 1000 TCID of the HIV laboratory isolates NL4-3. Infection was inhibited by adding mHSA (final concentration 50 μg/ml). Cell cultures 
were monitored 5 days after infection by visualization of induced syncytia and cell layer destruction after formalin fixation followed by a standard stain-
ing procedure (Hemacolor®, Merck). (d-f) To study inhibition of syncytia formation following transfection with pSVATGrev, cells were transfected with 
the expression plasmid and mHSA was added 30 min later. Syncytia were monitored after 28 h by standard phase contrast microscopy.Polzer et al. BMC Research Notes 2010, 3:155
http://www.biomedcentral.com/1756-0500/3/155
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shown in Figure 6, all NL4-3 mutants were neutralized
efficiently using 100-150 μg mHSA/ml. A significantly
higher sensitivity against mHSA was observed for X4
viruses and the viruses lacking N glycan g15.
Discussion
In the present study, we demonstrated that HOCl-modi-
fied serum albumins can bind to LAV gp120, and that
HOCl-modified serum albumins possess the ability to
efficiently neutralize entry of the NL4-3 laboratory strain.
Since the 5'-half of NL4-3 was constructed from NY5 and
the 3'-half from LAV the NL4-3 external envelope is iden-
tical to the commercial LAV gp120 used in our SPR bind-
ing studies.
Binding between the LAV gp120 and our inhibitor was
observed in a SPR assay with gp120 covalently linked to a
biosensor chip. Binding to gp120 was only monitored
with HOCl-modified serum albumin and non-modified
serum albumin showed no binding activity. As shown
before [16], mHSA binding is also specific to the West
Nile virus domain III and does bind to similar domains of
Yellow Fever and Dengue-2 virus, respectively. Since
mHSA also binds to WNV envelope, we suggest that the
binding of HOCl-modified serum albumin to HIV-1 or
WNV envelope is neither a highly epitope specific event
nor does it mirror a fundamental, yet undiscovered,
molecular step of the WNV or HIV-1 entry process. Such
non-specific binding events are common in many other
pathogen-host interactions. For example malaria para-
sites use negatively charged chondroitin-sulfate-proteo-
glycan (CSPG) structures to attach to the membrane
surface of their host cells [19]. For HIV-1, heparan-sul-
fate-proteoglycan (HSPG) is such an attachment factor
[20] and heparan sulphates as well as other polyanions
are efficient inhibitors of HIV-1 infection [21,22]. Our
current hypothesis is that pathogens which coat their
core particle with the membrane of the host cell need a
simple mechanism to attach to cells possessing an identi-
cal membrane structure. This membrane-membrane
contact must be mediated by the external envelope glyco-
protein complex present in the viral membrane and
might be a first non-specific binding event to initiate the
next step, binding to specific receptors.
Masking the envelope complex to prevent membrane
attachment seems to be a simple mechanism to prevent
viral entry. The blockade of CD4 and V3-loop antibody
binding by mHSA supports this hypothesis. The masking
by mHSA completely inhibited rCD4 binding and par-
tially inhibited the V3-loop antibody binding, indicating
that a large and important proportion of the gp120 mole-
cule is masked by mHSA. The surface of gp120 is per se
covered by complex carbohydrate structures, which rep-
resent more than 55% of the gp120 molecular weight.
Especially the elimination of the carbohydrate structure
g15 within the V3 loop plays an important role in viral
entry and these mutants showed higher infectivity. Due
to higher infectivity, these viruses can escape from neu-
tralizing antibodies present in human sera [23]. An inter-
esting advantage of mHSA is the ability to neutralize
these antibody resistant viruses. A more efficient neutral-
ization of such viruses by mHSA might be the result of
the lack of N-glycan g15 that renders the V3 loop more
exposed. Such an unmasked V3 loop seems to be a better
binding target for HOCl-modified albumins since the
binding of V3-loop-specific neutralizing antibodies was
blocked by mHSA. Masking the CD4 and V3 loop area by
Figure 6 Inhibition of X4, X4R5 and R5 tropic NL4-3 isolates by 
mHSA. (a) V3 loop amino acid sequences of NL4-3 mutants. NNT, rec-
ognition site for N-glycosylation. (b) TZM-bl cells were infected with vi-
rus supernatant representing an infectious dose of 500 foci/96-well. 
Infection was inhibited by adding mHSA (molar HSA:HOCl ratio 1:1000) 
to a final concentration of 1, 10, 50, 100 and 150 μg per ml of culture 
medium. Viral entry was monitored 2 days after infection by X-gal 
staining and counting of blue foci. Shown are the averages of triplicate 
wells. White symbols: X4 tropic viruses. Black symbols X4R5 (NL952) 
and R5 tropic viruses. The NL4-3 isolates were constructed by an ex-
change of the NL4-3 V3 loop against V3 loop sequences from primary 
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mHSA was also efficient for the blockade of CCR5-spe-
cific infection, but 3 times higher levels were necessary
compared to the neutralization of CXCR4-viruses. Thus,
V3-driven selection for higher infectivity of CXCR4
viruses or the switch from CCR5- to CXCR4-usage is not
beneficial for promoting escape from mHSA neutraliza-
tion. Blocking both coreceptor pathways is an important
step to block HIV-1 transmission. In an evolving epi-
demic, CXCR4-tropism is present in high frequency
among all HIV-1 subtypes except subtype C [24,25]. The
high frequency of CXCR4-tropism, 86% that was found in
subtype A and CRF02_AG in patient samples from West
Africa, demonstrates that a topical microbicide has to
inhibit CXCR4-viruses frequently present in HIV-1
infected individuals. On the other hand, cervico-vaginal
tissue preferentially supports the productive infection by
CCR5-tropic viruses [26]. Thus, a microbicide has to
block both coreceptor pathways to prevent HIV-1 sexual
transmission. The HOCl-modified serum albumins,
when applied as a topical microbicide, can be applied in
an adequate concentration (>200 μg/ml) that is high
enough to block both viruses completely.
In our experiments we added HOCl-modified serum
albumin directly into cell culture media. Viral infection
assays in cell culture have the advantage that cell culture
ingredients such as (i) antioxidants present in fetal calf
serum or (ii) free amino acids like methionine or cysteine
present in cell culture medium at 0.2 M are present dur-
ing the test period. In addition, the mHSA samples pro-
duced with low amounts of HOCl showed no inhibitory
effect indicating that potential traces of taurine or HOCl
are not contributing to the inhibitory effect. We also
tested our inhibitor in three different neutralization
assays using three different cell types (HeLa, GHOST and
TZM-bl) which are well established as host cells, widely
used in the HIV literature. Since virus is neutralized
under all these different cell culture conditions, all the cell
culture ingredients will not suppress the antiviral activity
of mHSA. Preincubation of cells with mHSA also had no
suppressive effect, showing that mHSA is not non-specif-
ically adsorbed by the cells or their different membrane
components. Moreover, the normal growth of other
viruses like yellow fever and dengue-2 virus in cell cul-
tures, over a period of up to 9 days, containing mHSA
[16] indicates that mHSA has no unspecific overall neu-
tralizing activity or toxic activity that inhibits cellular
growth and more especially viral production. We have
also tested mHSA in other sensitive cell culture systems
(Plasmodium falciparum growth in erythrocytes, Lassa-,
Marburg-, SARS virus growth) over a time period of 14
days (data not shown). In all these cell culture experi-
m e n t s  w e  o b s e r v e d  n o  i n h i b i t o r y  e f f e c t  o n  p a t h o g e n
growth indicating that mHSA in not a cellular toxin per
se.
The data implicate that mHSA, or a well defined struc-
ture thereof, might be applicable as a drug against viral
infection, and that the inoculation of mHSA into infected
individuals might overcome adaptive immune tolerance.
As was shown in animals, the active immunization of rats
with Freund's adjuvant together with a high dose of chlo-
rinated autoantigen induced an immune response against
the HOCl-modified protein [27]. Induction of autoanti-
body might be a risk factor in the direct application of
HOCl-modified proteins into body fluids but seems to be
no major problem when applied as a topical microbicide.
On the other hand, serum albumin is an important car-
rier for drugs and enzymes. In particular the transport of
the enzyme MPO across the endothelial barrier depends
on a specific interaction between HSA and MPO [28].
The HSA-binding epitope on MPO was identified as a
short linear region (aa 425-454), causing high-affinity
binding to HSA. The very close proximity of HSA and
MPO implicates that HSA might be highly susceptible for
MPO-dependent modifications. This also suggests that
MPO-modified serum albumin is a common self antigen
and therefore might be tolerated by the immune system.
It is known that HOCl is a powerful oxidant and modi-
fications of protein structure and function are well docu-
mented. In published studies, HOCl-induced
modifications were analyzed after treatment of peptides
or proteins with a 0.5-25-fold molar excess of HOCl
[18,29-31]. As shown by Vossmann et al. [16] as well as in
the present study, an antiviral activity of serum albumins
was observed only after treatment of serum albumin with
HOCl concentrations above the molar ratio of 1:100.
Using lower HOCl concentration, e.g. 1:10 or 1:50 we
were unable to detect any antiviral activity in our HIV-1
infection assays. This observation is important and dem-
onstrates that HOCl modifications, which occur under
low HOCl conditions [18,29-31] might be totally different
to those induced with higher HOCl concentrations as
shown here. Another minor aspect is that we have modi-
fied albumin at concentrations ≤ 1 mg protein/ml. When
serum albumin was treated with HOCl at higher concen-
trations, as described in the literature (10 mg/ml) [29], we
observed no inhibitory activity in our viral infection and
syncytium assays (data not shown). Thus, based on our
current knowledge, the antiviral activity of serum albu-
mins was induced in diluted aqueous solution and only
with a >100-fold molar excess of HOCl.
The modification of proteins by HOCl seems to be a
highly complex reaction. Data describing this process are
available mainly based on the structure analysis of modi-
fied amino acids or peptides at low HOCl concentration.
In a report by Salavej et al. [31], HSA was treated with
HOCl at a 25-fold molar excess, similar to the procedure
by Pattison et al. [18]. In their analysis, oxygenation was
detected for Trp238, Met147, Met353, and Met572, butPolzer et al. BMC Research Notes 2010, 3:155
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no chlorination of any of the HSA residues was detected.
Using HOBr, Salavej and coworkers detected the incorpo-
ration of one or two bromines at Tyr425, but no chlorina-
tion of any HSA residues was detected in HOCl treated
samples [31]. However, the treatment of amino acid resi-
dues with HOCl leads to the documented side chain
modifications, but HOCl-modification seems not to be
limited to these side chain products. In the context of a
linear peptide or protein HOCl-modified side chains
undergo intra- or inter-molecular cross linking. Thus, in
the context of a complex protein and probably under con-
ditions with excessive concentrations of HOCl, the pro-
cess is pushed towards the development of complex
protein conformations the nature of which is still
unknown. One final product of HOCl-treatment seems
to be the generation of stable antigenic epitopes on
human serum albumin.
Monoclonal antibodies against HOCl-induced
epitopes, have been produced. These monoclonal anti-
bodies were mainly raised against oxLDL. One of these
monoclonal antibodies was able to bind to the HOCl-
induced epitopes on HSA and based on this antibody
(clone 2D10G9) HOCl-modified proteins can be detected
in human tissue [13-15,29]. It was suggested that the
epitope recognized by this monoclonal antibody is of a
complex conformational type, but almost nothing is
known about the nature of the 2D10G9 epitope. The fact
that antibodies can be induced by immunization and
HOCl-induced epitopes can easily be detected in human
tissue [32] indicates that these HOCl-induced protein
structures are chemically and structurally related and
seem to be very stable.
Since a 100-fold molar excess of HOCl was necessary to
induce the antiviral activity, all the reactions and modifi-
cations documented at low HOCl-concentrations might
not explain the mechanism by which our HOCl-modified
serum albumins inhibit viral entry of HIV-1 as well as
West Nile virus. However, our study supports the hypoth-
esis that HOCl might be part of the host defense against
pathogens and apart from its direct toxic activity it may
have an additional indirect but important activity, the
transformation of a protein into an antiviral weapon [16].
From the cell culture experiments of Chase et al. and Kle-
banoff et al. [11,12], in which activated PMN cells release
MPO and HOCl was generated, HOCl was suggested as
the HIV-1-killing agent. Based on our results it is con-
ceivable that the generated HOCl reacts with bovine
serum albumin, which is usually present in high concen-
trations in cell culture media, and therefore mBSA would
be present during viral infection. As we have now demon-
strated, mBSA has a strong antiviral activity and might be
also responsible for the antiviral effects observed in PMN
cell cultures. The biological relevance of HOCl-modifica-
tion of serum albumin or other proteins might be ques-
tionable since virus replication in vivo is not limited to
inflammatory loci, where MPO is expressed in vivo lead-
ing to the production of HOCl. To our understanding, the
discovery of HOCl-modified serum albumin as an antivi-
ral agent opens a new field for the development of non-
toxic agents which can be added to blood products or can
be used as a local microbicide to prevent viral transmis-
sion. Since the neutralizing activity of HOCl-modified
serum albumins was documented against West Nile virus
and the HIV-1 NL4-3 mutants, irrespective to their core-
ceptor type, future work will show how efficient HOCl-
modified serum albumins can neutralize other HIV-1 and
HIV-2 variants as well as other viral species.
Taken together, the generation of HOCl-modified
serum albumins is very simple, cost effective and needs
no highly specialized laboratory equipment. We suggest
that HIV-1 neutralization by HOCl-modified serum albu-
mins is the result of masking the gp120 molecule. We
have shown that the CD4 binding site and other regions,
like the V3 loop, are partially masked by HOCl-modified
serum albumins. Masking the viral gp120/gp41 envelope
complex might be a simple but promising strategy to
inactivate HIV-1 and therefore prevent infection when
applied, for example, as a topical microbicide.
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